Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 71.70
+5.70 (8.64%)
At close: Mar 27, 2026
Shanghai Henlius Biotech Revenue
In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B CNY with 16.46% growth. Shanghai Henlius Biotech had revenue of 3.85B in the half year ending December 31, 2025, with 32.91% growth.
Revenue
6.67B CNY
Revenue Growth
+16.46%
P/S Ratio
5.25
Revenue / Employee
1.88M CNY
Employees
3,537
Market Cap
38.97B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.67B | 942.18M | 16.46% |
| Dec 31, 2024 | 5.72B | 329.54M | 6.11% |
| Dec 31, 2023 | 5.39B | 2.18B | 67.82% |
| Dec 31, 2022 | 3.21B | 1.53B | 91.07% |
| Dec 31, 2021 | 1.68B | 1.09B | 186.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 9.94B |
| Genscript Biotech | 7.47B |
| RemeGen | 3.62B |
| Shanghai Junshi Biosciences | 2.78B |
| InnoCare Pharma | 2.64B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
| Keymed Biosciences | 797.12M |